Weekly Brief / Issue 01
China Capital Markets Weekly: Inside Information and Asset Credit
New ABS guidance tests the underlying cash flow; an insider-trading interpretation moves attention to the start of a deal
7 min read

A receivable can look sound on paper and still depend on circular funding. Shanghai's revised ABS guidance addresses that problem, while a new judicial interpretation explains why inside information can exist before a board votes. IPO reviews of a robotics developer and a turbocharger manufacturer bring the discussion back to profitability and exchange-rate exposure.
Contents
A receivable is only as strong as its source of repayment
Shanghai's revised asset-backed securities guidance, published on July 24, asks a practical question: where will the cash that repays investors actually come from? That question matters when the asset being packaged is a receivable, a property-related claim or an interest in another securitization. A legal right to payment is not the same as a reliable, independently generated stream of cash.
The week also brought a revised judicial interpretation of insider trading. It directs attention to the early stages of a transaction, before the formal board process that outsiders usually associate with a corporate announcement. Meanwhile, IPO reviews of Dobot and Huaneng Turbine tested whether ambitious market narratives were supported by credible operating assumptions.

ABS review moves closer to the money
The Shanghai Stock Exchange's updated guidance took effect on publication and replaced its 2022 version. Its coverage includes property-related securitizations and structures that invest in other institutions' REIT products. The Shenzhen exchange also revised its ABS guidance. These are rules for reviewing securitizations, not changes to equity IPO admission standards.
One provision in Shanghai's text is particularly revealing. In a factoring arrangement, the price paid to acquire the receivable must not be funded by the debtor itself. Otherwise, money can appear to pass through a genuine asset purchase while the supposed source of repayment helps finance the purchase of its own obligation. The structure may be documented, but the cash does not necessarily provide the independent credit support that the investor expects.
The guidance also addresses cash segregation and related-party fairness. Segregation limits the risk that collections belonging to a securitization are mixed with an originator's other funds. Related-party review asks whether transactions inside a group are commercially justified, rather than assuming that a signed contract settles the question.
For a reader examining an ABS product, the sequence is straightforward: identify the underlying obligation, determine who pays it, trace how collections enter the structure, and establish who can use that money. The size of a pool or the strength of its originator cannot substitute for that analysis. Nor does an exchange's acceptance of a filing guarantee repayment.
Inside information can precede a board resolution
The Supreme People's Court published its revised insider-trading interpretation on July 24, with effect from July 27. Article 6 addresses when inside information forms, including the preliminary intention behind certain major matters. The relevant starting point need not be the date of a board resolution or a public announcement.
That changes how a transaction timeline should be read. Early negotiations, planning and contact with advisers may matter even when the final terms are unsettled. A company that monitors trading only after formal approval could miss the period in which sensitive information first became available to participants.
Article 9 also addresses lawful, pre-existing trading arrangements. The exception requires attention to the actual arrangement and its timing; it is not a general permission to trade simply because someone says a plan existed. For companies and advisers, dated instructions, access records and changes to a trading plan become important evidence. For investors, the interpretation helps explain why a regulator may examine trading well before the announcement that moved the price.
Robotics and turbochargers face different commercial tests
Dobot passed its July 22 committee review, but the result came with a specific request: make the projected timing of profitability and its risk disclosure more prudent. The committee questioned the basis for forecasting a return to profit in 2028, asking about competition, commercialization, orders, expenses and differences from domestic peers. A break-even forecast depends on those assumptions working together. Slower customer adoption or higher continuing research spending can move the date even when the technology performs as intended.
Changzhou Huaneng Turbine Power also passed its Beijing Stock Exchange review on July 22. The committee's question was about earnings stability: could exchange-rate movements lead to a substantial deterioration, and would the company's response measures work? That is a different test from a robotics developer's path to profitability. A turbocharger business can have established sales yet remain exposed to changes in the currency value of those sales.
The practical question is how a currency movement reaches the income statement. Pricing currency, the interval between shipment and payment, and hedging terms can affect both margins and exchange gains or losses. An assertion that exposure is managed needs an explanation of the amount covered and the period covered. Passing the committee does not turn that explanation into a guarantee of stable future earnings.
Registration does not produce a medicine's first sale
Evopoint, whose registration approval was published on July 23, illustrates the purpose of STAR Market's fifth listing standard. A biotechnology applicant without an approved medicine is not judged solely by current earnings. Its filing instead requires readers to distinguish drug development, licensing arrangements and the eventual sale of an approved product.
| Evopoint, CNY million, rounded | Q1 2026 |
|---|---|
| Revenue | 3.9 |
| Net loss | 147.2 |
| Net operating cash outflow | 139.5 |
Source: registration-stage prospectus, PDF pp.38–39. The quarterly financial statements were reviewed rather than audited.
The first-quarter revenue came mainly from material sales; the company had no approved drug generating product-sales revenue in that period. The loss and operating outflow show why the development timetable also needs a funding timetable. They are not proof that the pipeline will fail, but they make the interval before commercial receipts important.
Licensing adds a further distinction. An upfront payment or a milestone can fund research before a medicine reaches the market, while future payments depend on the terms of the agreement and the progress achieved. Readers should not assume that a large receipt will recur every quarter or that all projected milestones have already been earned. Registration in the securities market does not settle those commercial questions.
Selected IPO milestones
| Date | Applicant | Development |
|---|---|---|
| July 22 | Dobot | Passed the ChiNext committee; further work requested on profitability forecasts and risk disclosure |
| July 22 | Huaneng Turbine | Passed the Beijing committee; questioned on exchange-rate exposure and earnings stability |
| July 23 | Evopoint | Registration approval published |
These decisions illustrate why the stage and the substance of a review belong together. A committee pass moves an application forward; an outstanding request can still require changes to disclosure. Registration permits the next part of the offering process, but does not certify an applicant's commercial forecast.
Enforcement reaches the point of sale and the size of a contract
Regional measures highlighted failures that can occur far from a dramatic corporate scandal. Ningbo's action involving Guojin concerned staff assistance with suitability tests. Hunan's action involving Guzhanggui addressed unqualified activity and misleading return claims. Both concern how a financial service is sold, not merely what its formal documentation says.
The Jilin action concerning Jilin Jinguan Electric illustrates a different disclosure problem. A July 22 announcement reported approximately CNY252.34 million in successful project bids. The next day's correction reduced that figure to CNY157.05 million: the original disclosure overstated the amount by CNY95.29 million, or 37.76%. This was an error in the published bid amount, not evidence that a correctly reported contract subsequently shrank. The bureau issued warning letters to the company and four responsible officers. Fujian's action concerning Yango addressed a late 2025 bond report, while Beijing's private-fund measures concerned disclosure obligations under fund contracts.
The practical consequence for intermediaries is specific: suitability must reflect the client's answers, not answers supplied by staff; bid announcements need to reconcile to the underlying documents before publication; and an investor's contractual right to information must result in information being delivered. The week's rules and cases both turn on the same underlying task: follow the transaction beyond its label to the actual conduct and cash.
Sources
- Shanghai ABS review guidance, July 24
- Shanghai exchange explanation of the ABS revision
- Shenzhen ABS review guidance, July 24
- Supreme People's Court insider-trading interpretation
- CSRC registration approval for Evopoint
- Evopoint prospectus
- Dobot committee result, July 22
- Huaneng Turbine committee result, July 22
- Shanghai IPO project filings, Shenzhen IPO project filings, Beijing IPO project filings
- Ningbo measure, Hunan measure, Fujian measure, Jilin measure
Disclaimer
This article examines public records relating to the reporting period. It is for research and educational purposes and is not investment, legal or accounting advice, or a recommendation concerning any security. Official findings are attributed to the relevant authority; analytical observations are not findings of misconduct. Public documents may subsequently be corrected or supplemented.

